Company profile for Reunion Neuroscience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 serie...
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
30 Duncan Street Lower North Level Toronto, Ontario M5V 2C3
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/30/3158462/0/en/Reunion-Neuroscience-Announces-First-Patient-Dosed-in-REKINDLE-Phase-2-Clinical-Trial-of-RE104-for-the-Treatment-of-Adjustment-Disorder-AjD-in-Cancer-and-Other-Medical-Illnesses.html

GLOBENEWSWIRE
30 Sep 2025

https://www.globenewswire.com/news-release/2025/09/16/3150672/0/en/Reunion-Neuroscience-Announces-Final-Closing-of-its-Series-A-Financing-and-Plans-to-Advance-RE104-into-Clinical-Development-for-the-Treatment-of-Generalized-Anxiety-Disorder-GAD.html

GLOBENEWSWIRE
16 Sep 2025

https://www.fiercebiotech.com/biotech/reunions-psychedelic-prodrug-reduces-post-partum-depression-phase-2-study

FIERCE BIOTECH
18 Aug 2025

https://www.globenewswire.com/news-release/2025/08/18/3134924/0/en/Reunion-Neuroscience-Announces-Positive-Topline-Results-from-RECONNECT-Phase-2-Clinical-Trial-of-RE104-for-the-Treatment-of-Postpartum-Depression-PPD.html

GLOBENEWSWIRE
18 Aug 2025

https://www.globenewswire.com/news-release/2025/07/22/3119322/0/en/Reunion-Neuroscience-Announces-Publication-of-RE104-Phase-1-Data-in-The-Journal-of-Clinical-Psychopharmacology.html

GLOBENEWSWIRE
22 Jul 2025

https://www.globenewswire.com/news-release/2025/05/19/3083909/0/en/Reunion-Neuroscience-Announces-Last-Patient-Dosed-in-RECONNECT-Phase-2-Clinical-Trial-of-RE104-for-the-Treatment-of-Postpartum-Depression-PPD.html

GLOBENEWSWIRE
19 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty